Grund Nicholas 4

What Happened Nicholas Grund, Chief Commercial Officer of Akebia Therapeutics (AKBA), reported two sales on 2026-02-02 totaling 84,829 shares at $1.39 per share. The transactions: 53,585 shares for $74,483 and 31,244 shares for $43,429, for a combined proceeds of approximately $117,912. These were sales (not purchases); sales by insiders are often routine and can include planned program trades or withholding to cover taxes.

Key Details

• Transaction dates and prices: 2026-02-02 — 53,585 shares @ $1.39 ($74,483) and 31,244 shares @ $1.39 ($43,429).
• Total shares sold: 84,829; total proceeds: ~$117,912.
• Shares owned after transaction: not stated in the provided filing.
• Footnotes in the filing: F1 indicates a sale made pursuant to a Rule 10b5-1 trading plan adopted Sept 9, 2025; F2 and F3 indicate automatic issuer sales to cover tax withholding related to vesting/settlement of one-third of the reporting person's restricted stock units granted on Jan 31, 2024 and Jan 31, 2025.
• Filing date vs transaction date: Form filed 2026-02-04 reporting trades on 2026-02-02; this appears to be a timely filing.

Context

• One footnote shows a 10b5-1 plan (pre-established trading plan), which is a common way insiders execute scheduled sales. Two footnotes describe issuer-automated sales to satisfy tax withholding on RSU vesting—these are administrative and do not by themselves indicate a change in insider sentiment.
• Sales (S) and withholding (F) are different from purchases (P); purchases tend to be more informative about insider bullishness.